trending Market Intelligence /marketintelligence/en/news-insights/trending/tMD2cwSGsqLRONqu45bz3Q2 content esgSubNav
In This List

Portola secures $50M loan from Bristol-Myers Squibb, Pfizer

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Portola secures $50M loan from Bristol-Myers Squibb, Pfizer

Bristol-Myers Squibb Co. and Pfizer Inc. are lending $50 million to Portola Pharmaceuticals Inc. to help advance AndexXa, the company's potential antidote for Factor Xa inhibitors.

Bristol-Myers and Pfizer will each loan $25 million, the principal and interest of which will be repaid through royalties on AndexXa's commercial sales.

Portola is targeting regulatory approval of the drug in 2017, which is currently ongoing phase 3b/4 in patients with Factor Xa inhibitor-associated acute major bleeding.

Bristol-Myers Squibb and Pfizer have been collaborating with Portola Pharmaceuticals on the drug in exchange for rights in certain countries.